Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax® Reports Year End 2008 Financial Results
March 27th, 2009
Affymax, Inc. (Nasdaq:AFFY) reported financial results for the year ended December 31, 2008. The net loss for the year 2008 was $86.5 million compared to a net loss of $43.1 million for the year ended December 31, 2007. Affymax recognized revenue for the year ended December 31, 2008 of $82.9 million compared to $44.3 million for the year ended December 31, 2007. The increase in revenue was the result of higher collaboration revenue from its partnership with Takeda Pharmaceutical Company Limited, under their 2006 collaboration for development of Affymax’s lead compound, Hematide™. Research and development expenses for the year ended December 31, 2008...
Source: Health Business Week (2009-03-27)
|
